Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET
Company Participants
Diane Weiser - Senior Vice President of Corporate Communications & Investor Relations
Robert Blum - President & Chief Executive Officer
Fady Malik - Executive Vice President, Research & Development
Stuart Kupfer - Vice President & Chief Medical Officer
Andrew Callos - EVP & Chief Commercial Officer
Robert Wong - Vice President & Chief Accounting Officer
Ching Jaw - Senior Vice President & Chief Financial Officer
Conference Call Participants
Joe Pantginis - H.C. Wainwright
Dane Leone - Raymond James
Salim Syed - Mizuho
Serge Belanger - Needham
Jason Butler - JMP Securities
Srikripa Devarakonda - Truist Securities
Yasmeen Rahimi - Piper Sandler
Charles Duncan - Cantor
Roanna Ruiz - Leerink Partners
Justin Kim - Oppenheimer & Co.
Operator
Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics Third Quarter 2023 Conference Call. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen-only mode. At the company's request, we will open the call for questions-and-answers after the presentation. We will allow for one question per participant.
I'll now turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Diane Weiser
Good afternoon, and thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments. Fady Malik, EVP of R&D will provide updates related to aficamten focused to SEQUOIA-HCM and FOREST-HCM; Stuart Kupfer, SVP and Chief Medical Officer will provide additional updates for aficamten relating to SEQUOIA-HCM and MAPLE-HCM, and we’ll also discuss our early-stage pipeline, inclusive of CK-586 and CK-136. Andrew Callos, EVP and Chief Commercial Officer will discuss commercial readiness activities for aficamten. Robert Wong, VP and Chief Accounting Officer will provide a financial overview of the past quarter; and Ching Jaw, SVP and Chief Financial Officer will discuss our financial outlook and corporate development strategies. And finally, Robert Blum will provide closing comments and review upcoming expected key milestones.
Please note that portions of the following discussion, including our responses to questions, contain statements that relate to future events and performance rather than historical facts and constitute forward-looking statements. Our actual results might differ materially from those projected in these forward-looking statements.
Additional information concerning factors that could cause our actual results to differ materially from those in these forward-looking statements is contained in our SEC filings, including our current report regarding our third quarter 2023 financial results filed on Form 8-K that was furnished to the SEC today. We undertake no obligation to update any forward-looking statements after this call.